Cytokine Profiles Characterized in Primary Sjögren´s Syndrome Patients
By LabMedica International staff writers Posted on 02 Dec 2020 |
Image: The Bio-Plex Pro Human Th17 Cytokine Panel enables measurement of analytes in diverse matrices such as serum, plasma, and cell culture supernatants (Photo courtesy of Bio-Rad).
Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by a lymphocytic infiltrate in salivary glands driving to epithelial damage. The pSS patients present heterogenic clinical and serological characteristics.
Cytokines play an essential role in pSS pathogenesis, mediating cell response and promoting tissue damage. Th1, Th2, and Th17 cells and their cytokine profiles have been implied in the pathogenesis of pSS as well as reported in saliva, serum, and labial salivary gland (LSG), with different results.
Biomedical Scientists from the Universidad de Guadalajara (Guadalajara, México) included in a study 99 pSS patients, diagnosed by the 2016 ACR/EULAR classification criteria, and 76 control subjects (CS). Ninety‐eight percent of the pSS patients had a positive biopsy of labial minor salivary glands (focus score ≥ 1 foci/4 mm2).
The team collected samples in tubes containing spray‐coated silica and a polymer gel were used for serum separation (BD Vacutainer SST, Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Cytokine quantification (IL‐1β, IL‐4, IL‐6, IL‐10, IL‐17A, IL‐17F, IL‐21, IL‐22, IL‐23, IL‐25, IL‐31, IL‐33, IFN‐γ, and TNF‐α) was performed by Bio‐Plex Pro Human Th17 Cytokine Panel 15‐Plex kit and analyzed using a Bio‐Plex MAGPIX Multiplex Reader (Bio‐Rad Laboratories, Inc, Hercules CA, USA).
The investigators reported that higher IFN‐γ, IL‐17F, IL‐21, IL‐23, IL‐4, and IL‐31 levels were observed in pSS patients in comparison with control subjects. Principal component analysis (PCA) showed three groups. The severe group was characterized by higher cytokine concentrations as well as an increase in clinical parameters such as antibody levels, damage index score, and others. The moderate group presented intermediate severity; meanwhile, the mild group presented the lowest severity. The population showed low positivity to anti‐Ro (13.3%) and anti‐La (11.1%) antibodies.
The authors concluded that cluster analysis revealed three groups that were different in cytokine levels and clinical parameters in which the mild group was defined by lower severity, the moderate group with intermediate severity, and the severe group with higher severity. This analysis could help sub-classify the primary Sjögren’s syndrome patients for a better understanding of the clinical phenotype that impacts the treatment approach. The study was published on October 17, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Universidad de Guadalajara
Becton, Dickinson and Company
Bio‐Rad Laboratories
Cytokines play an essential role in pSS pathogenesis, mediating cell response and promoting tissue damage. Th1, Th2, and Th17 cells and their cytokine profiles have been implied in the pathogenesis of pSS as well as reported in saliva, serum, and labial salivary gland (LSG), with different results.
Biomedical Scientists from the Universidad de Guadalajara (Guadalajara, México) included in a study 99 pSS patients, diagnosed by the 2016 ACR/EULAR classification criteria, and 76 control subjects (CS). Ninety‐eight percent of the pSS patients had a positive biopsy of labial minor salivary glands (focus score ≥ 1 foci/4 mm2).
The team collected samples in tubes containing spray‐coated silica and a polymer gel were used for serum separation (BD Vacutainer SST, Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Cytokine quantification (IL‐1β, IL‐4, IL‐6, IL‐10, IL‐17A, IL‐17F, IL‐21, IL‐22, IL‐23, IL‐25, IL‐31, IL‐33, IFN‐γ, and TNF‐α) was performed by Bio‐Plex Pro Human Th17 Cytokine Panel 15‐Plex kit and analyzed using a Bio‐Plex MAGPIX Multiplex Reader (Bio‐Rad Laboratories, Inc, Hercules CA, USA).
The investigators reported that higher IFN‐γ, IL‐17F, IL‐21, IL‐23, IL‐4, and IL‐31 levels were observed in pSS patients in comparison with control subjects. Principal component analysis (PCA) showed three groups. The severe group was characterized by higher cytokine concentrations as well as an increase in clinical parameters such as antibody levels, damage index score, and others. The moderate group presented intermediate severity; meanwhile, the mild group presented the lowest severity. The population showed low positivity to anti‐Ro (13.3%) and anti‐La (11.1%) antibodies.
The authors concluded that cluster analysis revealed three groups that were different in cytokine levels and clinical parameters in which the mild group was defined by lower severity, the moderate group with intermediate severity, and the severe group with higher severity. This analysis could help sub-classify the primary Sjögren’s syndrome patients for a better understanding of the clinical phenotype that impacts the treatment approach. The study was published on October 17, 2020 in the Journal of Clinical Laboratory Analysis.
Related Links:
Universidad de Guadalajara
Becton, Dickinson and Company
Bio‐Rad Laboratories
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms